Assessment of the Cytocompatibility of a Novel 45S5 Bioactive Glass Based Intracanal Medicament with Human Periodontal Ligament Fibroblasts Using MTT Assay
BG-45S5 showed good short-term cytocompatibility at 1–10 µg/mL with concentration-dependent metabolic suppression at 25–50 µg/mL with concentration-dependent metabolic suppression at 25–50 µg/mL and may be suitable for intracanal application at biologically acceptable concentrations.